Danielle Grate
Medical · Carson City, NVNPI 1356415558
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 332 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$963
- Lilly USA, LLC$865
- Corcept Therapeutics$753
- Amgen$711
- Mannkind Corporation$561
- Boehringer Ingelheim$422
- plus $5K from 32 others
Across 1 payment — averaging $156.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$156
What the payments were for
- Food & beverage$8,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 30 | $963 |
| Lilly USA, LLC | 34 | $865 |
| Corcept Therapeutics | 23 | $753 |
| Amgen(2 entities) | 35 | $711 |
| Mannkind Corporation | 18 | $561 |
| Boehringer Ingelheim | 18 | $422 |
| Novo Nordisk | 11 | $386 |
| Xeris Pharmaceuticals, Inc. | 25 | $384 |
| Sanofi-aventis U.S. LLC | 12 | $373 |
| AstraZeneca(2 entities) | 12 | $346 |
| Dexcom, Inc. | 6 | $335 |
| Bayer | 12 | $300 |
| Abbott | 12 | $247 |
| Radius Health, Inc. | 9 | $243 |
| Ascendis Pharma Endocrinology Inc | 6 | $218 |
| Recordati_rare_diseases_inc. | 9 | $214 |
| AbbVie | 9 | $198 |
| Antares Pharma, Inc. | 7 | $165 |
| Ascensia Diabetes Care US Inc. | 5 | $146 |
| GRT US Holding, Inc. | 6 | $126 |
| Almatica Pharma LLC | 5 | $117 |
| Kyowa Kirin, Inc. | 5 | $115 |
| Insulet Corporation | 1 | $95 |
| Astellas Pharma US Inc | 3 | $88 |
| Madrigal Pharmaceuticals | 2 | $68 |
| Tandem Diabetes Care, Inc. | 2 | $52 |
| Chiesi USA, Inc. | 2 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $48 |
| IBSA Pharma Inc. | 2 | $40 |
| Halozyme Inc | 1 | $28 |
| Alvogen Inc | 1 | $26 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| BETA Bionics, Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| RGH Enterprises LLC | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$266
- AFREZZA$228
- DEXCOM G6 TRANSMITTER$150
- Saxenda$111
How this compares
$8,832 in reported general payments places this provider in the 90th percentile of 250 medical providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $146,683 |
| OzempicSemaglutide | 57 | $115,002 |
| MounjaroTirzepatide | 71 | $105,678 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $36,747 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $33,752 |
| AfrezzaInsulin Regular, Human | 12 | $32,852 |
| TrulicityDulaglutide | 14 | $27,413 |
| FarxigaDapagliflozin Propanediol | 14 | $22,178 |
| SynthroidLevothyroxine Sodium | 183 | $20,607 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $19,248 |
| VascepaIcosapent Ethyl | 20 | $17,970 |
| InvokanaCanagliflozin | 17 | $16,908 |
| FiaspInsulin Aspart (Niacinamide) | 17 | $13,807 |
| NovologInsulin Aspart | 18 | $6,812 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $422 | $180,435158 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $865 | $137,82796 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $386 | $135,62192 claims |
| Mannkind CorporationAfrezza | $561 | $32,85212 claims |
| AbbVieSynthroid, Armour Thyroid | $198 | $23,291209 claims |
| AstraZenecaFarxiga | $346 | $22,17814 claims |
| PfizerLevoxyl | $23 | $2,01154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 medical providers in Nevada.
Other medical in Carson City
- McKenzie CombaCarson City$9K
- Ana TurnerCarson City$8K
- Kate McElroyCarson City$4K
- Jennifer McCordCarson City$3K
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.